Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hironori Ryota is active.

Publication


Featured researches published by Hironori Ryota.


Journal of Hepato-biliary-pancreatic Sciences | 2014

Pancreaticogastrostomy following distal pancreatectomy prevents pancreatic fistula‐related complications

Hiroaki Yanagimoto; Sohei Satoi; Hideyoshi Toyokawa; Tomohisa Yamamoto; Satoshi Hirooka; Jun Yamao; So Yamaki; Hironori Ryota; Yoichi Matsui; A-Hon Kwon

The most common postoperative complication after distal pancreatectomy (DP) is still postoperative pancreatic fistula (POPF), which is closely associated with other major complications and remains an unsolved problem.


Journal of Hepato-biliary-pancreatic Sciences | 2014

Less morbidity after introduction of a new departmental policy for patients who undergo open distal pancreatectomy

Rintaro Yui; Sohei Satoi; Hideyoshi Toyokawa; Hiroaki Yanagimoto; Tomohisa Yamamoto; Satoshi Hirooka; So Yamaki; Hironori Ryota; Taku Michiura; Kentaro Inoue; Yoichi Matsui; A-Hon Kwon

The aim of this study was to retrospectively compare morbidity and mortality before and after introduction of a new departmental policy for patients who undergo distal pancreatectomy.


Journal of Hepato-biliary-pancreatic Sciences | 2016

Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial.

Sohei Satoi; Masayuki Sho; Hiroaki Yanagimoto; Tomohisa Yamamoto; Takahiro Akahori; Shoichi Kinoshita; Minako Nagai; Satoshi Hirooka; So Yamaki; Satoshi Nishiwada; Hironori Ryota; Naoya Ikeda; Yoshiyuki Nakajima; Masanori Kon

The aim of this randomized controlled trial (RCT) was to investigate whether pancrelipase protects against nonalcoholic fatty liver disease (NAFLD) development after pancreatoduodenectomy in patients with pancreatic cancer better than conventional pancreatic enzyme supplementation.


Nutrition and Cancer | 2016

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Hiroaki Yanagimoto; Sohei Satoi; Tomohisa Yamamoto; Satoshi Hirooka; So Yamaki; Masaya Kotsuka; Hironori Ryota; Taku Michiura; Kentaro Inoue; Yoichi Matsui; Koji Tsuta; Masanori Kon

ABSTRACT The present study was conducted to determine whether active hexose correlated compound (AHCC), a functional food extracted from cultured basidiomycetes, possesses the potential to attenuate adverse events in unresectable pancreas ductal adenocarcinoma (PDAC) patients receiving chemotherapy. Unresectable PDAC patients receiving gemcitabine treatment (GEM) as the first-line chemotherapy were prospectively divided into 2 groups according to AHCC intake (AHCC group, n = 35) or not (control group, n = 40). The patients in the AHCC group ingested 6.0 g of AHCC for 2 mo. Hematological and nonhematological toxicity was compared between the AHCC and control groups. The C-reactive protein (CRP) elevation and albumin decline of the AHCC group were significantly suppressed as compared to the control group during the GEM administration (P = 0.0012, P = 0.0007). Patients in the AHCC group had less frequency of taste disorder caused by GEM (17% vs. 56%, P = 0.0007). Frequency of grade 3 in the modified Glasgow Prognostic Score (mGPS) during chemotherapy was found significantly less in the AHCC group (14%) than the control group (53%, P = 0.0005). AHCC intake can be effective in reducing the adverse events associated with chemotherapy and may contribute to maintaining the QOL of patients with PDAC during GEM administration.


International Journal of Surgery Case Reports | 2015

Low-grade mucinous neoplasia in a cecal diverticulum: A case report

Kazuyoshi Nakatani; Katsuji Tokuhara; Tatsuma Sakaguchi; Hironori Ryota; Kazuhiko Yoshioka; Masanori Kon

Highlights • There are no previous reports of mucocele disease in a colonic diverticulum worldwide.• Laparoscopic ileocecal resection was chosen because of its minimal invasiveness and the patient had no evidence of recurrence 12 months postoperatively.• The possibility of a mucocele in a colonic diverticulum should be considered in patients with a colonic SMT.


Diagnostic Cytopathology | 2018

Cytological features of hepatoid adenocarcinoma of the gallbladder: A case report with immunocytochemical analyzes

Saya Yoshioka; Mitsuaki Ishida; Kimiaki Okano; Kaori Sandoh; Yusuke Ebisu; Chika Miyasaka; Tomohisa Yamamoto; Hironori Ryota; Sohei Satoi; Koji Tsuta

Hepatoid adenocarcinoma is defined as an extrahepatic malignant neoplasm showing morphological and immunohistochemical resemblance of hepatocellular carcinoma. The occurrence of this type of tumor in the gallbladder is extremely rare. In this study, we report the first cytological case of hepatoid adenocarcinoma of the gallbladder. An 80‐year‐old Japanese female was found to have a tumorous lesion in the gallbladder. Papanicolaou smear of the ascites demonstrated a few epithelial cell clusters composed of round to oval neoplastic cells with distinct cell border and large centrally‐located nuclei. Tumor touch smear of the resected tumor revealed the presence of two distinct neoplastic components. The first component was composed of clusters or sheets of epithelial cells with distinct cell border, relatively rich clear cytoplasm, and centrally‐located nuclei, as seen in the ascites specimen. The other component was composed of tall columnar cells with large basally‐oriented nuclei, and glandular formation was noted as well. Immunocytochemical analyzes of the touch smear material demonstrated that the former component was positive for HepPar1, thus it was considered as a hepatoid adenocarcinoma, and the latter component deemed as a typical adenocarcinoma. Histopathological and immunohistochemical examination of the resected gallbladder tumor confirmed a diagnosis of hepatoid adenocarcinoma. The characteristic cytological features of hepatoid adenocarcinoma are the presence of sheets or clusters of neoplastic cells with distinct cell border and centrally‐located nuclei. Immunocytochemical analysis for HepPar1 may help its diagnosis. Demonstration of hepatoid adenocarcinoma is important in the cytological specimen because this type of tumor shows an aggressive clinical course.


Annals of Gastroenterological Surgery | 2018

Clinical impact of developing better practices at the institutional level on surgical outcomes after distal pancreatectomy in 1515 patients: Domestic audit of the Japanese Society of Pancreatic Surgery

Sohei Satoi; Tomohisa Yamamoto; Fuyuhiko Motoi; Ippei Matsumoto; Hideyuki Yoshitomi; Ryosuke Amano; Munenori Tahara; Yoshiaki Murakami; Hidehito Arimitsu; Seiko Hirono; Masayuki Sho; Hironori Ryota; Masayuki Ohtsuka; Michiaki Unno; Yoshifumi Takeyama; Hiroki Yamaue

Institutional standardization in the perioperative management of distal pancreatectomy (DP) has not been evaluated in a multicenter setting. The aim of the present study was to assess the influence of institutional standardization on the development of postoperative complications after DP.


World Journal of Surgical Oncology | 2015

A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma

Sohei Satoi; Hiroaki Yanagimoto; Tomohisa Yamamoto; Hideyoshi Toyokawa; Satoshi Hirooka; So Yamaki; Singh Sapam Opendro; Kentaro Inoue; Taku Michiura; Hironori Ryota; Yoichi Matsui; Masanori Kon


International Journal of Clinical Oncology | 2017

PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining

So Yamaki; Hiroaki Yanagimoto; Koji Tsuta; Hironori Ryota; Masanori Kon


Surgery Today | 2017

Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy

Sohei Satoi; Hiroaki Yanagimoto; Tomohisa Yamamoto; Chisato Ohe; Chika Miyasaka; Yoshiko Uemura; Satoshi Hirooka; So Yamaki; Hironori Ryota; Taku Michiura; Kentaro Inoue; Yoichi Matsui; Noboru Tanigawa; Masanori Kon

Collaboration


Dive into the Hironori Ryota's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sohei Satoi

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Satoshi Hirooka

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

So Yamaki

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Masanori Kon

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Yoichi Matsui

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Koji Tsuta

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Masaya Kotsuka

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge